Apollo plans to acquire GSK's patent expired medicine business

Source: Biovalley 2014-11-18 as the patent cliff approaches, many biopharmaceutical companies have to face the siege of the best-selling drugs they develop from cheap generic drugs It is also this opportunity that the famous private investment company Apollo global management focuses on the manufacturers of these best-selling drugs Recently, it was revealed that Apollo global management offered GlaxoSmithKline 3 billion US dollars for some of its drugs that lost patent protection Among them are GlaxoSmithKline's antidepressant drug Paxi, migraine drug imitrex, stomach acid reducing drug Zantac and seasickness drug Zofran It is estimated that the total sales of these drugs in 2014 is close to $1.4 billion, but with the erosion of market share by generic drugs, the sales of these drugs will be severely tested However, Apollo global management is not the first buyer to make such a calculation In August, famous investors such as KKR, Warburg Pincus, Blackstone capital and Bain Capital planned to acquire relevant departments of GlaxoSmithKline and Novartis and merge them into a new biomedical company Of course, GlaxoSmithKline also has its own small calculation Considering that these drugs will occupy an important position in the market of developing countries even if they lose patent protection, GlaxoSmithKline reserves its relevant rights in emerging markets Just as the so-called hero thinks the same, many pharmaceutical giants see that once generic drugs enter their own fields, it will bring huge impact to their related businesses, so they are looking for potential buyers for similar transactions Among them are Abbott, Johnson & Johnson and MSD GlaxoSmithKline, in the midst of the news, is clearly not prepared to comment The company is now working hard to complete a business swap agreement with Novartis According to the agreement, Novartis will acquire the cancer R & D Department of GSK, and GSK will obtain the vaccine business of Novartis.